drugset / Trial / NCT07432997
Pharmacological Enhancement of Glymphatic Function in Humans
Phase 1/2
Completed
31 enrolled
Applied Cognition
Stanford University · collabWashington State University · collab
Non-randomizedCrossoverDouble-blindTreatment
Summary
Alzheimer's disease is linked in part to the buildup of harmful proteins in the brain, including amyloid and tau. Most current treatments aim to remove these proteins directly. This study explores a different approach: helping the brain clear waste more effectively during sleep. The investigators will test whether certain medications can safely boost the brain's natural "cleaning system," known as the glymphatic system, in healthy older adults. Participants will receive controlled sleep treatments and blood tests to measure protein clearance. If successful, this strategy could support new therapies that work alongside existing Alzheimer's treatments.
Timeline
- Start
- 2023-12-11
- Primary completion
- 2024-09-13
- Completion
- 2024-09-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dexmedetomidine | Other / unclassified | — | — |
| Comparator | Midodrine | Small molecule | — | — |